Conditions: Sarcoma; Soft Tissue Sarcoma; Metastatic Sarcoma; Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Leiomyosarcoma; Liposarcoma; Angiosarcoma; Synovial Sarcoma; Rhabdomyosarcoma; Spindle Cell Sarcoma; High Grade Sarcoma; Bone Sarcoma
Interventions: Drug: Gemcitabine; Drug: Docetaxel; Drug: 9-ING-41
Sponsors: Brown University; Actuate Therapeutics Inc.
Not yet recruiting
Feeds
20859 items (20859 unread) in 74 feeds
Acinar Cell Carcinoma
(201 unread)
Acinic Cell Carcinoma
(104 unread)
Adenoid Cystic Carcinoma
(367 unread)
Adrenal Gland Cancer
(1718 unread)
Ampulla Of Vater
(213 unread)
Anal Cancer
(1799 unread)
Angiosarcoma
(359 unread)
Appendix Cancer
(450 unread)
Bile Duct Cancer
(2698 unread)
Brain and CNS
(2597 unread)
Carcinoid
(671 unread)
Endocrine/Neuroendocrine
(2404 unread)
Gall Bladder Cancer
(1146 unread)
Hemangioendothelioma
(506 unread)
Hepatoblastoma
(366 unread)
Pancreas
(416 unread)
Phyllodes
(215 unread)
PMP and Mucinous Tumors
(242 unread)
Rhabdomyosarcoma
(772 unread)
Sarcoma
(3615 unread)
Trial - Rhabdomyosarcoma (24 unread)
-
9-ING-41Combined With Chemotherapy in Adolescents and Adults
Posted: May 28th, 2021, 2:00pm GMT
-
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Posted: May 25th, 2021, 2:00pm GMT
Conditions: Recurrent Solid Tumor; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Wilms Tumor; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma
Interventions: Drug: Onivyde; Drug: Talazoparib; Drug: Temozolomide
Sponsors: St. Jude Children's Research Hospital; Pfizer; Ipsen
Recruiting -
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Posted: May 21st, 2021, 2:00pm GMT
Conditions: Pediatric Solid Tumor; Osteosarcoma; Rhabdomyosarcoma; Neuroblastoma; Ewing Sarcoma; Wilms Tumor; Adrenocortical Cancer; Desmoplastic Small Round Cell Tumor; Germ Cell Cancer; Rhabdoid Tumor; Clear Cell Sarcoma; Hepatoblastoma; Melanoma; Carcinoma; Malignant Peripheral Nerve Sheath Tumors; Soft Tissue Sarcoma
Interventions: Drug: Fludarabine; Drug: Cyclophosphamide; Drug: MESNA; Drug: B7-H3 CAR T cells
Sponsor: St. Jude Children's Research Hospital
Not yet recruiting -
Phase 1/2 Study of Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors
Posted: May 18th, 2021, 2:00pm GMT
Conditions: Sarcoma, Ewing; Rhabdomyosarcoma
Interventions: Drug: PEN-866; Drug: Vincristine; Drug: Temozolomide
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
Indo-cyanine Green (ICG) in Paediatric Oncology MIS
Posted: April 22nd, 2021, 2:00pm GMT
Conditions: Pediatric Renal Tumor; Metastatic Osteosarcoma; Metastatic Ewing Sarcoma; Pulmonary Metastasis; Rhabdomyosarcoma; Non-Rhabdo. Soft Tissue Sarcoma
Intervention: Drug: Indocyanine green
Sponsor: Birmingham Women's and Children's NHS Foundation Trust
Not yet recruiting -
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
Posted: March 10th, 2021, 3:00pm GMT
Conditions: Solid Tumors; Soft Tissue Sarcoma; Ewing Sarcoma; Malignant Epithelial Neoplasm; Rhabdomyosarcoma; Wilms Tumor; Hepatic Tumor; Germ Cell Tumor; Bone Metastases
Interventions: Device: Magnetic Resonance-Guided High Intensity Focused Ultrasound; Drug: Lyso-thermosensitive Liposomal Doxorubicin
Sponsor: Children's National Research Institute
Not yet recruiting -
Molecular Characterization of Genetic Alterations in Pediatric Solid Tumors
Posted: February 26th, 2021, 3:00pm GMT
Condition: Pediatric Solid Tumors
Intervention:
Sponsor: National Council of Scientific and Technical Research, Argentina
Recruiting -
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Posted: July 23rd, 2020, 2:00pm GMT
Conditions: Pediatric Solid Tumor; Germ Cell Tumor; Retinoblastoma; Hepatoblastoma; Wilms Tumor; Rhabdoid Tumor; Carcinoma; Osteosarcoma; Ewing Sarcoma; Rhabdomyosarcoma; Synovial Sarcoma; Clear Cell Sarcoma; Malignant Peripheral Nerve Sheath Tumors; Desmoplastic Small Round Cell Tumor; Soft Tissue Sarcoma; Neuroblastoma; Melanoma
Interventions: Biological: second generation 4-1BBζ B7H3-EGFRt-DHFR; Biological: second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG
Sponsor: Seattle Children's Hospital
Recruiting -
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Posted: May 7th, 2020, 2:00pm GMT
Conditions: Liver Cancer; Rhabdomyosarcoma; Malignant Rhabdoid Tumor; Liposarcoma; Wilms Tumor; Yolk Sac Tumor
Interventions: Genetic: AGAR T cells; Drug: Cytoxan; Drug: Fludara
Sponsors: Baylor College of Medicine; Center for Cell and Gene Therapy, Baylor College of Medicine
Not yet recruiting -
Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma
Posted: March 6th, 2020, 3:00pm GMT
Condition: Rhabdomyosarcoma
Interventions: Drug: Vinorelbine; Drug: Mocetinostat
Sponsors: Jonsson Comprehensive Cancer Center; Mirati Therapeutics Inc.; Phase One Foundation
Recruiting -
A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma
Posted: September 19th, 2019, 2:00pm GMT
Conditions: Desmoplastic Small Round Cell Tumor; Rhabdomyosarcoma
Interventions: Drug: Prexasertib; Drug: Irinotecan
Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting -
Indocyanine Green (ICG) Guided Tumor Resection
Posted: September 10th, 2019, 2:00pm GMT
Conditions: Neoplastic Disease; Solid Tumor
Intervention: Drug: Indocyanine Green
Sponsor: St. Jude Children's Research Hospital
Recruiting -
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Posted: October 17th, 2018, 2:00pm GMT
Conditions: Solid Tumors; Ewing Sarcoma; Rhabdoid Tumor; Rhabdomyosarcoma; Neuroblastoma; Medulloblastoma; Diffuse Intrinsic Pontine Glioma
Interventions: Drug: Palbociclib; Drug: Temozolomide; Drug: Irinotecan; Drug: Topotecan; Drug: Cyclophosphamide
Sponsor: Pfizer
Recruiting -
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Posted: August 7th, 2018, 2:00pm GMT
Conditions: Pediatric Solid Tumor; Germ Cell Tumor; Retinoblastoma; Hepatoblastoma; Wilms Tumor; Rhabdoid Tumor; Carcinoma; Osteosarcoma; Ewing Sarcoma; Rhabdomyosarcoma; Synovial Sarcoma; Clear Cell Sarcoma; Malignant Peripheral Nerve Sheath Tumors; Desmoplastic Small Round Cell Tumor; Soft Tissue Sarcoma; Neuroblastoma
Interventions: Biological: second generation 4-1BBζ EGFR806-EGFRt; Biological: second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
Sponsor: Seattle Children's Hospital
Recruiting -
Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
Posted: March 27th, 2018, 2:00pm GMT
Conditions: Pediatric Solid Tumor; Pediatric Lymphoma; Pediatric Brain Tumor; DIPG; Neuroblastoma; Ewing Sarcoma; Rhabdomyosarcoma; Osteosarcoma
Intervention: Drug: CLR 131
Sponsor: Cellectar Biosciences, Inc.
Recruiting -
Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy
Posted: March 22nd, 2018, 2:00pm GMT
Condition: Sarcoma,Soft Tissue
Interventions: Combination Product: Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery; Combination Product: 2 cycles of atezolizumab followed by surgery then post-operative radiotherapy; Combination Product: Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.
Sponsors: Centre Leon Berard; Roche Pharma AG
Recruiting -
International PPB/DICER1 Registry
Posted: December 22nd, 2017, 3:00pm GMT
Conditions: Pleuropulmonary Blastoma; Sertoli-Leydig Cell Tumor; DICER1 Syndrome; Cystic Nephroma; Wilms Tumor; Pineoblastoma; Renal Sarcoma; Nodular Hyperplasia of Thyroid; Nasal Chondromesenchymal Hamartoma; Ciliary Body Medulloepithelioma; Neuroblastoma; Pituitary Cancer; Embryonal Rhabdomyosarcoma
Intervention:
Sponsors: Children's Hospitals and Clinics of Minnesota; Children's National Research Institute; Washington University School of Medicine; ResourcePath, LLC; Beijing Children's Hospital; University of Cambridge; Emory University; Dana-Farber Cancer Institute
Recruiting -
Comparison of Safety and Efficacy of Detaenial Sigmoid Neobladder and Ileal Neobladder
Posted: April 11th, 2017, 2:00pm GMT
Conditions: Bladder Cancer; Urinary Diversion
Interventions: Procedure: sigmoid; Procedure: ileal
Sponsors: Zhujiang Hospital; Sun Yat-sen University; The Third Affiliated Hospital of Southern Medical University; Fourth Affiliated Hospital of Guangxi Medical University
Recruiting -
Familial Investigations of Childhood Cancer Predisposition
Posted: February 10th, 2017, 3:00pm GMT
Conditions: Acute Leukemia; Adenomatous Polyposis; Adrenocortical Carcinoma; AML; BAP1 Tumor Predisposition Syndrome; Carney Complex; Choroid Plexus Carcinoma; Constitutional Mismatch Repair Deficiency Syndrome; Diamond-Blackfan Anemia; DICER1 Syndrome; Dyskeratosis Congenita; Emberger Syndrome; Familial Acute Myeloid Leukemia; Familial Adenomatous Polyposis; Fanconi Anemia; Familial Cancer; Familial Wilms Tumor; Familial Neuroblastoma; GIST; Hereditary Breast and Ovarian Cancer; Hereditary Paraganglioma-Pheochromocytoma Syndrome; Hodgkin Lymphoma; Juvenile Polyposis; Li-Fraumeni Syndrome; Lynch Syndrome; MDS; Melanoma Syndrome; Multiple Endocrine Neoplasia Type 1; Multiple Endocrine Neoplasia Type 2; Neuroblastoma; Neurofibromatosis Type 1; Neurofibromatosis Type II; Nevoid Basal Cell Carcinoma Syndrome; Non Hodgkin Lymphoma; Noonan Syndrome and Other Rasopathy; Overgrowth Syndromes; Pancreatic Cancer; Peutz-Jeghers Syndrome; Pheochromocytoma/Paraganglioma; PTEN Hamartoma Tumor Syndrome; Retinoblastoma; Rhabdoid Tumor Predisposition Syndrome; Rhabdomyosarcoma; Rothmund-Thomson Syndrome; Tuberous Sclerosis; Von Hippel-Lindau Disease
Intervention:
Sponsor: St. Jude Children's Research Hospital
Recruiting -
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
Posted: February 3rd, 2017, 3:00pm GMT
Conditions: Rhabdomyosarcoma; Rhabdomyosarcoma- Alveolar; Rhabdomyosarcoma-Embryonal
Interventions: Drug: Dasatinib; Drug: Ganitumab
Sponsor: National Cancer Institute (NCI)
Recruiting -
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
Posted: October 26th, 2016, 2:00pm GMT
Conditions: Osteosarcoma; Ewing Sarcoma; Rhabdomyosarcoma; Soft Tissue Sarcoma
Interventions: Drug: nab-Paclitaxel; Drug: Gemcitabine
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; National Pediatric Cancer Foundation
Recruiting -
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Posted: September 7th, 2016, 2:00pm GMT
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia; Non Hodgkin Lymphoma; Hodgkin Lymphoma; Myeloproliferative Syndromes; Plasma Cell Myeloma; Colon Carcinoma; Adenocarcinoma of Rectum; Soft Tissue Sarcoma; Ewing's Sarcoma; Rhabdomyosarcoma
Interventions: Biological: Natural Killer (NK) Cells; Biological: ALT803
Sponsor: David Wald
Recruiting -
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
Posted: July 24th, 2015, 2:00pm GMT
Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Hodgkin Lymphoma; Non-Hodgkin Lymphoma; Myelodysplastic Syndrome; Myeloproliferative Syndrome; Rhabdomyosarcoma; Ewing Sarcoma; Primitive Neuroectodermal Tumor; Osteosarcoma; Neuroblastoma
Interventions: Procedure: TCRαβ+/CD19+ depleted Haploidentical HSCT; Drug: Zoledronate
Sponsor: University of Wisconsin, Madison
Recruiting -
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Posted: March 5th, 2013, 3:00pm GMT
Condition: Refractory and/or Relapsed Metastatic Solid Tumors
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Radiation: low dose total body irradiation; Drug: Melphalan; Drug: Tacrolimus
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recruiting